IL7 and glioblastoma: The long‐acting engineered version of IL‐7 (rhIL‐7‐hyFc) immunotherapy could restore lymphocyte count and maintain elevated TLC when administered with conventional systemic therapy in recurrent GBM patients without serious adverse events.